422513-13-1 Usage
Description
Hesperadin is a multi-kinase inhibitor, characterized as an oxindole derivative with specific substitutions that contribute to its biological activity. It is known for its ability to inhibit human Aurora kinase B and other kinases, playing a significant role in the regulation of cell division and exhibiting potential applications in various fields due to its inhibitory effects on cell proliferation and kinase activity.
Uses
Used in Cancer Treatment:
Hesperadin is used as an anticancer agent, targeting aurora kinases and affecting the regulation of chromosomes during mitosis. This action leads to the inhibition of cell proliferation and the induction of polyploidy and defects in cytokinesis and spindle assembly, making it a promising compound for the development of cancer therapeutics.
Used in Antiviral Applications:
Hesperadin is used as an antiviral agent, specifically against clinical isolates of influenza A and B viruses. It inhibits viral replication with EC50 values ranging from 0.22 to 2.21 μM, demonstrating its potential in the development of antiviral treatments.
Used in Parasitic Infections Treatment:
Hesperadin is used as an antiparasitic agent, showing efficacy against T. brucei, L. major promastigotes and amastigotes, and P. falciparum with EC50 values ranging from 0.01 to 2.37 μM. This highlights its potential in the treatment of parasitic infections, although it has shown less activity against T. cruzi.
Used in Cellular Research:
Hesperadin is used as a research tool for studying the role of Aurora kinases and other targeted kinases in cell division, chromosome alignment, and segregation. Its ability to induce mitotic arrest and affect cell proliferation makes it a valuable compound for understanding the molecular mechanisms underlying these processes.
references
[1]jetton n1, rothberg kg, hubbard jg, wise j, li y, ball hl, ruben l. the cell cycle as a therapeutic target against trypanosoma brucei: hesperadin inhibits aurora kinase-1 and blocks mitotic progression in bloodstream forms. mol microbiol. 2009 apr;72(2):442-58. doi: 10.1111/j.1365-2958.2009.06657.x. epub 2009 mar 6.[2]hauf s1, cole rw, laterra s, zimmer c, schnapp g, walter r, heckel a, van meel j, rieder cl, peters jm. the small molecule hesperadin reveals a role for aurora b in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. j cell biol. 2003 apr 28;161(2):281-94. epub 2003 apr 21.
Check Digit Verification of cas no
The CAS Registry Mumber 422513-13-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,2,2,5,1 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 422513-13:
(8*4)+(7*2)+(6*2)+(5*5)+(4*1)+(3*3)+(2*1)+(1*3)=101
101 % 10 = 1
So 422513-13-1 is a valid CAS Registry Number.
422513-13-1Relevant articles and documents
Synthesis of the Kinase Inhibitors Nintedanib, Hesperadin, and Their Analogues Using the Eschenmoser Coupling Reaction
Hanusek, Ji?í,Marek, Luká?,Svoboda, Jan,Váňa, Ji?í
, p. 10621 - 10629 (2021/07/31)
A novel synthetic approach involving an Eschenmoser coupling reaction of substituted 3-bromooxindoles (H, 6-Cl, 6-COOMe, 5-NO2) with two substituted thiobenzanilides in dimethylformamide or acetonitrile was used for the synthesis of eight kinase inhibitor
